Table 4.

Most Frequently Reported AEs with UPA in U-ACHIEVE Maintenance Study

AEs N (%)	UPA 15 mg, N=148	UPA 30 mg, N=154	PBO, N=149
Nasopharyngitis	18 (12.2)	22 (14.3)	15 (10.1)
Elevation of creatine phosphokinase	9 (6.1)	13 (8.4)	3 (2.0)
UC exacerbation	19 (12.8)	11 (7.1)	45 (30.2)
Upper respiratory tract infections	7 (4.7)	9 (5.8)	6 (4.0)
Arthralgia	9 (6.1)	5 (3.2)	15 (10.1)
Anemia	7 (4.7)	1 (0.6)	6 (4.0)

Abbreviations: AEs, adverse events; UPA, upadacitinib; PBO, placebo; UC, ulcerative colitis.